Cholesterol levels out of control amongst Italians: a strategy to save lives and 3.7 billion in expenditure
Almost half of those hospitalised for a heart attack were not on treatment: a panel of experts has issued guidelines to tackle the ‘lack of awareness’ regarding one of the main cardiovascular risk factors
Over a quarter of Italians aged between 35 and 74 have high cholesterol, but 40.7 per cent are unaware of this, 35.5 per cent are aware of it but do not seek treatment, and just 23.8 per cent are receiving treatment; amongst those undergoing treatment, fewer than two in ten (19.4 per cent) achieve the recommended levels for their risk category. The litmus test of this massive ‘neglect’ of one of the main cardiovascular risk factors – as highlighted by the Italian National Institute of Health – is that almost half of those hospitalised for a heart attack in 2025 were not receiving treatment for LDL cholesterol, the ‘bad’ sort. Yet this is one of the primary threats that needs to be addressed: every reduction of around 39 mg/dL lowers the risk of stroke and heart attack by 20–25 per cent. This scenario forms the basis for the Cardiotarget-LDL Observatory for Cardiovascular Health project, which led to yesterday’s presentation to the Chamber of Deputies of the ‘2026–2030 Agenda for the Management of Dyslipidaemia and the Reduction of Cardiovascular Risk’, with the non-conditional support of the Menarini Group.
The document is guided by the latest guidelines from the European Society of Cardiology (ESC) and was drawn up by an Advisory Board comprising 24 experts from leading cardiometabolic scientific societies, general practice, the pharmaceutical sector, institutions and patient organisations. Today, cardiovascular diseases cause almost 225,000 deaths and over 930,000 hospital admissions a year in Italia, at a direct cost of around 21.3 billion euros: a strategy is needed comprising targeted prevention, timely diagnosis, appropriate treatment, regular check-ups and adherence to treatment. Bringing all patients up to the target set by the European recommendations would yield potential savings of 3.7 billion euros in direct healthcare expenditure, even taking into account that each patient ‘outside the target range’ costs up to 2,000 euros more.
Filippo Crea, president-elect of the European Society of Cardiology (ESC), provides an overview: ‘European and US scientific societies have set out particularly important treatment targets for hypercholesterolaemia, diabetes and high blood pressure. These guidelines are supported by a vast body of clinical studies which have confirmed that meeting these targets not only prolongs life but also improves its quality, because whilst a stroke does not necessarily kill, it can leave a person in a wheelchair. The problem – continues the professor, head of the Gemelli-Isola Centre of Excellence in Cardiovascular Sciences in Rome – is that the guidelines are not being followed in Italia any more than they are elsewhere in the world, to the extent that, globally, only 50–60 per cent of patients achieve the targets.” Crea then speaks of ‘statin-phobia’: ‘Despite prescriptions, patients replace statins with dietary supplements – which have a market worth 10–15 billion a year in Europe alone – for reasons not based on science. All this contributes to the fact that we are a long way from eliminating traditional risk factors: despite the proven efficacy of the available medicines, there is widespread under-use of these drugs, which, moreover, are not even particularly expensive’. To these issues must be added the contribution of the ‘exposome’, which accounts for half of cardiovascular risk: we are talking about exposure to air, noise and light pollution, to depression and social isolation, as well as to infectious diseases, with an ‘incredible under-use of vaccinations amongst citizens frightened by fake news’, explains Filippo Crea.
So what is the solution? Cardiotarget sets out four priorities: preventing the onset of the disease in healthy individuals, slowing its progression in those already affected, reducing deaths and hospital admissions, and stabilising cardiovascular healthcare expenditure despite an ageing population. These ‘macro’ objectives – to be measured by a National Observatory for Cardiovascular Health – are to be pursued through very concrete actions: among these, the updating of AIFA Note 13 “which sets out less ambitious targets than the European guidelines”, which would result in savings of 842 million euros (Drei estimate based on Clicon data and meta-analyses), a National Plan for Cardiometabolic Population Health Management; diagnostic and therapeutic pathways (PDTA) linking hospitals and the local community, with specialist ‘mentors’ for GPs; local centres for cardiology management modelled on the diabetes model; pharmacies acting as ‘health points’; check-ups 4–6 weeks after discharge and then at 6–12 months; community nurses acting as ‘case managers’. Finally, extensive training and education, as a cultural shift is needed: amongst doctors – through courses on cardio-renal management and communication with patients – in schools and workplaces, as well as in supermarkets and gyms. ‘The responsibility is shared,’ summarises Filippo Crea, ‘among politicians, doctors and the patients themselves, in making the best use of the resources we have.’ Meanwhile, from 23 November, Cardiotarget will be organising free prevention days in two pilot regions – Lombardy and Campania – in collaboration with GPs and pharmacies: the results will lead, in spring 2027, to a policy document setting out priorities, interventions and measurable objectives.

